Microdosimetric concepts in radioimmunotherapy
- PMID: 8492762
- DOI: 10.1118/1.597049
Microdosimetric concepts in radioimmunotherapy
Abstract
In microdosimetry particular emphasis is placed on the stochastic fluctuation of dose in small target volumes such as individual cell nuclei or chromatin fiber, and their relevance to radiobiologic toxicity. Thus microdosimetry is intimately associated with models of radiation action. There are three principal areas where microdosimetry has been applied: (1) radiation protection, (2) high LET radiotherapy, e.g., neutron therapy, and (3) incorporated radionuclides, and in this latter category the importance of microdosimetry to the radiobiology of radiolabeled antibodies is becoming increasingly recognized. The objective of microdosimetry is the complete characterization of energy deposition within all target volumes throughout the tissue of interest. The importance and relevance of this pursuit will depend upon the properties of the radionuclide emissions and the spatial distribution of the radionuclide relative to the target volumes. If the distribution of internal emitters within both malignant and normal tissue is uniform, the application of microdosimetry to radioimmunotherapy (RIT) is limited to alpha-emitters and Auger emitters. Under such circumstances the traditional MIRD formalism for the evaluation of tumor and tissue doses from the commonly used beta-emitters is entirely adequate. This, however, is rarely the case. When the distribution of radiolabeled antibody is nonuniform, techniques of dose averaging over volumes greater in size than the individual target volumes can become inadequate predictors of the biological effect. The concepts, methods, and realm of applicability of microdosimetry within the field of radioimmunotherapy are emphasized in this paper.
Similar articles
-
Analytic microdosimetry for radioimmunotherapeutic alpha emitters.Med Phys. 1992 Nov-Dec;19(6):1385-93. doi: 10.1118/1.596770. Med Phys. 1992. PMID: 1461200
-
Experimental radioimmunotherapy.Med Phys. 1993 Mar-Apr;20(2 Pt 2):551-67. doi: 10.1118/1.597142. Med Phys. 1993. PMID: 8492764 Review.
-
Comparison of different classes of radionuclides for potential use in radioimmunotherapy.Hell J Nucl Med. 2007 May-Aug;10(2):82-8. Hell J Nucl Med. 2007. PMID: 17684582 Review.
-
Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry.Med Phys. 1993 Mar-Apr;20(2 Pt 2):601-10. doi: 10.1118/1.597055. Med Phys. 1993. PMID: 8492769 Review.
-
Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.Cancer Biother Radiopharm. 2001 Oct;16(5):391-400. doi: 10.1089/108497801753354294. Cancer Biother Radiopharm. 2001. PMID: 11776756
Cited by
-
Cancer radioimmunotherapy with alpha-emitting nuclides.Eur J Nucl Med Mol Imaging. 2005 May;32(5):601-14. doi: 10.1007/s00259-005-1803-2. Eur J Nucl Med Mol Imaging. 2005. PMID: 15841373 Review.
-
Scission-Enhanced Molecular Imaging (SEMI).Bioconjug Chem. 2024 Sep 10;35(10):1543-52. doi: 10.1021/acs.bioconjchem.4c00337. Online ahead of print. Bioconjug Chem. 2024. PMID: 39255972
-
Monte Carlo investigation of electron specific energy distribution in a single cell model.Radiat Environ Biophys. 2020 Mar;59(1):161-171. doi: 10.1007/s00411-019-00815-z. Epub 2019 Oct 28. Radiat Environ Biophys. 2020. PMID: 31659434
-
Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis.Bioconjug Chem. 2008 Apr;19(4):958-65. doi: 10.1021/bc700413r. Epub 2008 Mar 14. Bioconjug Chem. 2008. PMID: 18338858 Free PMC article.
-
Targeted α-particle therapy of bone metastases in prostate cancer.Clin Nucl Med. 2013 Dec;38(12):966-71. doi: 10.1097/RLU.0000000000000290. Clin Nucl Med. 2013. PMID: 24212441 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources